AbbVie | ABBV - PE Price to Earnings


AbbVie reported 23.03 in PE Price to Earnings for its fiscal quarter ending in March of 2026.





Pe Change Date
AbbVie 23.03 1 Mar/2026
Abbott 24.94 5.78 Mar/2026
ALKERMES 39.33 19.8 Mar/2026
Amgen 19.84 5.47 Mar/2026
AstraZeneca 29.59 2.3 Mar/2026
Biogen 13.7 0.32 Mar/2026
BioMarin Pharmaceutical 15.28 3.96 Mar/2026
Bristol-Myers Squibb 9.08 0.2 Mar/2026
Eisai 35.61 8.98 Mar/2026
Eli Lilly 40.27 0.06 Mar/2026
Gilead Sciences 17.7 2.07 Mar/2026
GlaxoSmithKline 14.87 3.72 Mar/2026
J&J 29.43 4.9 Jun/2026
Medtronic 19.66 3.1 Mar/2026
Merck 16.52 2.6 Mar/2026
Neurocrine Biosciences 28.09 807.38 Mar/2026
Novartis 20.17 2.32 Mar/2026
Pacira 38.58 14.1 Mar/2026
Perrigo 27.45 31.51 Mar/2026
Pfizer 9.32 5.16 Mar/2026
Regeneron Pharmaceuticals 25.14 7.03 Mar/2026
Roche Holding 16.09 3.51 Dec/2025
Sanofi 11.84 0.14 Mar/2026
UCB 29.7 5.52 Dec/2025
United Therapeutics 20.42 3.1 Mar/2026
Vertex Pharmaceuticals 25.82 0.33 Mar/2026
Zoetis 18.8 1.62 Mar/2026